8-K: Pasithea Therapeutics Gets Nasdaq Bid Price Extension

Pasithea Therapeutics Corp. has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement, now until February 16, 2027.

Summary

• Pasithea Therapeutics Corp. received a notification from Nasdaq on August 20, 2026, indicating it has been granted an additional 180-day extension to comply with the Minimum Bid Price Requirement.
• The company was previously notified on February 20, 2026, that it was not in compliance with the $1.00 minimum bid price for its common stock.
• The initial grace period was set to expire on August 19, 2026.
• The new deadline to regain compliance is February 16, 2027.
• Pasithea Therapeutics Corp. is considering options to regain compliance, including a potential reverse stock split.
• Failure to regain compliance by the new deadline could result in the delisting of the company's common stock from Nasdaq.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development due to the continued non-compliance with Nasdaq's minimum bid price requirement, despite an extended grace period.

Positives

• An additional 180-day extension has been granted by Nasdaq to regain compliance with the minimum bid price requirement.
• The company continues to be listed on The Nasdaq Capital Market while working towards compliance.

Negatives

• The company remains non-compliant with Nasdaq's Minimum Bid Price Requirement of $1.00 per share.
• The stock's closing bid price has been below $1.00 for at least 30 consecutive business days.
• There is no assurance that the company will regain compliance within the extended period.
• Potential delisting from Nasdaq is a risk if compliance is not achieved.

Risks

• Failure to regain compliance with the Minimum Bid Price Requirement by February 16, 2027, will lead to delisting from Nasdaq.
• The company may need to implement a reverse stock split, which can be perceived negatively by the market.
• Continued non-compliance could negatively impact investor confidence and the company's ability to raise capital.

Future Outlook

The company will continue to monitor its stock's closing bid price and may consider options such as a reverse stock split to regain compliance with Nasdaq's Minimum Bid Price Requirement by February 16, 2027. There is no guarantee of regaining compliance.

Management Comments

• The Company will continue to monitor the closing bid price of its Common Stock and may, if appropriate, consider implementing available options, including but not limited to, implementing a reverse stock split of its outstanding securities, to regain compliance with the Minimum Bid Price Requirement.

Industry Context

StockSavvy.ai notes that maintaining listing on major exchanges like Nasdaq is crucial for investor confidence and liquidity. Companies facing bid price deficiencies often explore reverse stock splits, though these can be viewed unfavorably by the market if not accompanied by fundamental improvements.

Stakeholder Impact

• Shareholders: Potential for continued stock price pressure and the risk of delisting, which could reduce liquidity and market value. A reverse stock split could also impact perception.
• Creditors: Continued listing on Nasdaq provides a degree of stability, but ongoing compliance issues could indirectly affect creditworthiness.
• Employees: Uncertainty surrounding the company's listing status could impact morale and retention.

Next Steps

• Monitor the closing bid price of the Common Stock.
• Consider implementing available options, such as a reverse stock split, to regain compliance.
• Regain compliance with the Minimum Bid Price Requirement by February 16, 2027.
• If compliance is not regained, prepare for potential delisting and appeal to a Nasdaq hearings panel.

Key Dates

Recommendation

The company has been granted an extension to regain Nasdaq compliance, which temporarily avoids immediate delisting. However, the underlying issue of a low stock price persists, and the consideration of a reverse stock split indicates a lack of organic growth. While not a strong sell due to the extension, the significant risk of delisting and lack of positive catalysts warrant a cautious 'hold' stance.

Keywords

Nasdaq compliance, Minimum Bid Price, Delisting risk, Reverse stock split, Securities Exchange Act, Form 8-K, Pasithea Therapeutics